86 studies on THYMOSIN-ALPHA-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 86 dated studies on THYMOSIN-ALPHA-1. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $15.00 | $13.00–$17.00 | $3.00 | 2 sources · 2 offers |
| 10 mg | $22.50 | $19.50–$25.00 | $2.25 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
The lack of established therapy for hepatitis C non-responders with cirrhosis represents a critical unmet medical need, as these patients face a high risk of progressive liver disease, liver failure, and hepatocellula…
If successful, this study could demonstrate a novel adjuvant strategy to improve outcomes for patients with early-stage Non-Small Cell Lung Cancer (NSCLC). By targeting circulating tumor cells (CTCs) and immunosenesce…
This research is significant because improving the completion rate of immunotherapy could drastically enhance long-term outcomes for locally advanced NSCLC patients. Thymosin α-1 is an immunomodulatory peptide known f…
If the combinations involving Thymosin alpha 1 proved effective, this research could lead to new, more potent treatment regimens for patients suffering from advanced malignant melanoma. Identifying synergistic effects…
Successful outcomes from this trial could significantly improve vaccine efficacy for older adults, a demographic particularly susceptible to severe COVID-19. If proven effective, Thymalfasin could become a valuable ad…
For HBeAg-positive chronic hepatitis B patients, especially those with long-term entecavir exposure, achieving HBeAg seroconversion and sustained viral suppression remains a significant challenge, often requiring life…
This trial addresses a critical unmet need for improving immune function in cancer patients, as lymphocytopenia severely compromises the body's ability to fight infections and potentially control cancer progression. I…
This study is significant because it explored a potential new strategy for hepatitis C patients who had exhausted standard treatment options. Identifying effective therapies for non-responders is critical to prevent p…
The provided research abstract focuses on the study's objectives and design, rather than presenting specific results from the completed trial. Therefore, detailed quantitative findings regarding the safety profile, sp…
As this study is "NOT_YET_RECRUITING" and is scheduled to commence in February 2026, there are no actual findings or results to report at this time. However, the primary objective is to rigorously evaluate the efficac…
Chronic Hepatitis B remains a significant global health burden, and new strategies to improve treatment outcomes are urgently needed, particularly for HBeAg-positive patients who often have higher viral loads and dise…
The provided trial registration (NCT00082082) outlines the study's objective and design but does not include any specific efficacy or safety results from the completed trial. Therefore, we cannot report quantitative d…
If Thymosin Alpha 1 were to demonstrate a benefit, it could represent a valuable new therapeutic option for patients with metastatic NSCLC, particularly those who do not qualify for targeted therapies due to their EGF…
This clinical trial was withdrawn before completion, and consequently, no results regarding efficacy, safety, or immune response were reported. Therefore, no data on time to progression, objective response rate, or sp…
This study addresses a significant clinical challenge by investigating a promising strategy to bolster the immune system in a highly vulnerable patient population undergoing major cardiac surgery. If Thymosin α1 prove…
The findings from this Phase II trial, once fully published, could be highly significant. If the combination of PEG-Tα1 and adefovir demonstrates superior efficacy in achieving HBeAg seroconversion and HBV DNA suppres…
HBV-induced cirrhosis is a major global health burden, and finding strategies to reverse liver scarring is critical for improving patient outcomes and preventing complications like liver cancer. If the combination of …
This study is significant because it investigates a novel multi-modal approach combining chemotherapy, radiotherapy, and two distinct immunotherapies for a challenging subset of rectal cancer. If successful, this regi…
The ongoing global health challenge posed by COVID-19 highlights the critical need for effective therapeutic interventions, especially for vulnerable populations like those with lymphocytopenia. While this pilot study…
This Phase II study (NCT ID: NCT02542137) was unfortunately WITHDRAWN before any patients could be enrolled or treated, meaning no experimental data was collected or reported. > The most significant finding is that th…
This ambitious Phase II trial represents a significant effort to push the boundaries of locally advanced NSCLC treatment by integrating multiple advanced therapeutic strategies. If successful, this regimen could offer…
This study addresses a critical unmet need for improving long-term outcomes and reducing recurrence rates in high-risk colorectal cancer patients. If Thymosin-alpha 1 proves effective, it could offer a novel, immune-m…
Improving monocyte function is paramount for restoring the immune system's ability to fight infection and prevent further organ damage in sepsis, potentially leading to reduced mortality and improved patient recovery.…
Optimizing treatment duration for chronic hepatitis B is crucial for improving patient compliance, minimizing potential side effects, and reducing overall healthcare costs. If a shorter, yet equally effective, duratio…
This study represents a significant step towards developing more potent treatments for limited-stage SCLC, a disease with historically poor prognosis. By combining established chemotherapy and radiotherapy with dual i…
This study is significant because it investigates a potential new therapeutic strategy for HIV-positive patients struggling with immune reconstitution disorders, a condition that can severely impact quality of life an…
This research is significant because HBV/HDV co-infection is a severe and challenging condition with limited treatment options. The potential of REP 2139-Ca to directly target HBsAg, which is crucial for both HBV and …
This adaptive platform trial design represents a significant methodological advancement in clinical research for ARDS, enabling the efficient and simultaneous evaluation of numerous potential therapies within a single…
The successful completion and verification of previous findings in this rigorous clinical trial represent a significant step forward for sepsis treatment. Thymosin Alpha 1 (Ta1) is an immunomodulatory peptide that cou…
This trial holds significant promise as it investigates a novel approach to potentiate the effectiveness of neoadjuvant therapy for resectable NSCLC, a patient population with high unmet medical needs. If the addition…
If successful, this trial could demonstrate that recombinant human interferon alpha-1b nasal drops, potentially combined with thymosin alpha 1, offer a safe and effective strategy for preventing 2019-nCOV infection. T…
This study is significant because it explores a novel strategy to enhance anti-tumor immunity in a challenging patient population: metastatic NSCLC patients with stable disease after initial TKI therapy. The bold comb…
Preventing infections is paramount for improving survival and quality of life in patients undergoing allogeneic hematopoietic transplantation. If Thymosin Alfa 1 demonstrates a favorable safety profile and preliminary…
If successful, this study could establish Thymosin Alpha1 as a novel therapeutic option for a challenging condition with limited current treatments. Given the widespread prevalence of osteoporotic pain in the elderly,…
Free, no account — handy when you're working with THYMOSIN-ALPHA-1.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account